Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
Hiro

234 results about "Synovitis" patented technology

Synovitis is the medical term for inflammation of the synovial membrane. This membrane lines joints that possess cavities, known as synovial joints. The condition is usually painful, particularly when the joint is moved. The joint usually swells due to synovial fluid collection.

Composition and Method for Treating Connective Tissue Damage

The present invention provides a composition, and a method of use thereof for treating connective tissue damage in man and in animals, which comprises a therapeutically effective amount of chondroitin sulfate, N-acetyl D-glucosamine, and hyaluronan (hyaluronic acid). Particularly, the present invention provides a composition, and a method of use thereof, for treating connective tissue damage including, but not limited to, arthritic disease, osteoarthritis, rheumatoid arthritis, osterochondrosis dessicans, cartilage damage, joint injury, joint inflammation, joint synovitis, degenerative joint disease (DJD), post surgical DJD, traumatic injury, fracture, tendon damage, ligament damage, skeletal damage, musculoskeletal damage, fiber damage, adipose tissue damage, blood cell damage, and plasma damage. Compositions for delivery of the present invention include those for parenteral, oral, and transmucosal delivery and for direct surgical placement onto the affected tissues.
Owner:ARTHRODYNAMIC HLDG LLC

Temperature-sensitive in-situ gel preparation composition for anticular injection and preparation method thereof

The invention relates to a temperature-sensitive in-situ gel preparation composition for intra-articular injection and a preparation method thereof, and belongs to the field of medicine preparations. The preparation method comprises the following steps: preparing diclofenac sodium-carrying sodium alginate microspheres by combining a microsphere technology with a temperature-sensitive gel technology, and then carrying the medicine-carrying microspheres in a chitosan / beta-sodium glycerophosphate temperature-sensitive in-situ gel system to obtain a diclofenac sodium in-situ gel preparation composition. The composition is in a liquid state at a room temperature, capable of being converted to a semi-solid gel at a body temperature and forming a medicine storeroom at a medication part after being partially injected to enter an articular cavity, and beneficial to slowly releasing the medicine, prolonging the time of staying at the injection part, of the medicine, and enhancing the efficacy. The composition disclosed by the invention can be used for treating arthritis diseases of rheumatism, rheumatoid arthritis, osteoarthritis, synovitis and the like, as well as applicable to both diclofenac sodium and other arthritis treatment medicines of non-steroidal anti-inflammatory medicines, steroid hormone medicines, biological preparations and the like.
Owner:CHINA PHARM UNIV

Articular cavity inner injecting and administering reparations containing trehalose

The present invention provides an intra-articular injection administration preparation containing trehalose, which is characterized in that the preparation contains the trehalose. The present invention can improve the capabilities of the cartilage cells to adapt to and resistant to the environmental changes through the intra-articular injection administration, at the same time, the trehalose has the significant effects of antioxidant and anti-free radicals, which can alleviate the symptoms of arthritis; in addition, the trehalose also provides the necessary sugar for cartilage repair, so as to repair and reconstruct the cartilage. The present invention is used for improving and treating the rheumatism, rheumatoid arthritis, osteoarthritis, synovitis and / or cartilage injury.
Owner:SHANDONG ACADEMY OF PHARMACEUTICAL SCIENCES

Medicament for treating arthralgia and myalgia

The invention relates to a medicament for treating arthralgia and myalgia. The medicament is prepare from the components in parts by weight as follows: 1000 parts of nux vomica, 100 parts of radix clematidis, 100 parts of caulis sinomenii, 100 parts of garden balsam stem, 100 parts of lycopodium clavatum, 100 parts of berba aristolochiae mollissimae, 100 parts of monkshood, 100 parts of radix aconiti agrestis, 100 parts of the root of red-rooted salvia, 100 parts of angelica sinensis, 100 parts of rheum officinale, 100 parts of dragon's blood, 100 parts of semen momordicae, 100 parts of eucommia ulmoides, 100 parts of cinnamon, 100 parts of radix angelicae pubescentis, 100 parts of notopterygium root, 100 parts of asarum, 100 parts of radix achyranthis bidentatae, 100 parts of homalomena occulta, 100 parts of anisetree bark, 100 parts of radices sileris, 100 parts of caper, 100 parts of monkshood, 100 parts of ligusticum wallichii, 100 parts of Chinese polyphaga, 100 parts of scorpio, 100 parts of centipede, 100 parts of frankincense, 100 parts of myrrh, 100 parts of leech, 60 parts of camphor, 60 parts of borneol, 20 parts of musk and 300 parts of zaocys dhumnade. The medicament provided by the invention can be used for treating cervical spondylosis, brain swelling cervical pain, scapulohumeral periarthritis, scapula back pain, pelvospondylitis, thoracic vertebra pain, elbow joint pain, pain in waist and lower extremities, lumbar disc herniation, cervical and lumbar spinal stenosis, osteoproliferation, ischiadic nerve pain, knee-joint dropsy, synovitis, knee pain and rheumatic arthritis.
Owner:曹佳庚

Compound medicament for treating synovitis

InactiveCN101199778AAdjust immune functionRestoration of joint mobilityAntipyreticAnalgesicsExternal applicationCodonopsis
The invention discloses a combined drug for treating synovitis, including an oral drug and an external application drug. The part rate of the oral drug is that Rhizoma Atractylodis 10-20 parts, Cortex Phellodendri 10-20 parts, Radix Stephaniae Tetrandrae 10-20 parts, Chaenomeles sinensis 10-20 parts, Harms Manyprickle Acanthopanax 10-20 parts, Radix Clematidis Chinensis 10-20 parts, Radix Angelicae Pubescentis 10-20 parts, Radix Paeoniae Alba 10-20 parts, Radix Astragali 30-60 parts, Semen Coicis 30-60 parts, Radix Codonopsis 30-60 parts, Radix Angelicae Dahuricae 8-15 parts and Ramulus Cinnamomi 8-15 parts. The part rate of the external application drug is that Radix Aconiti Kusnezoffii 2-20 parts, Radix Aconiti, 5-10 parts, Rhizoma et Radix Notopterygii 5-20 parts, Flos Carthami 5-10 parts, Radix Saposhnikoviae 10-20 parts, Ramulus Cinnamomi 5-10 parts, Ramulus Mori 2-5 parts, Rhizoma Atractylodis 5-10 parts, Radix Aconiti Lateralis Preparata 10-20 parts, Herba Epimedii 5-10 parts, Caulis Impatientis 10-20 parts, Radix Angelicae Pubescentis 10-20 parts, Radix Angelicae Dahuricae 10-20 parts and Herba Asari 10-20 parts. The combined drug of the invention achieves the potency of drug to be directly delivered to the focus through oral taking, local suffocating and foment and realizes good treatment effect.
Owner:杨纪英
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products